Ricerca avanzata

Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 1998 Ottobre;39(5) > The Journal of Cardiovascular Surgery 1998 Ottobre;39(5):551-5

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE JOURNAL OF CARDIOVASCULAR SURGERY

Rivista di Chirurgia Cardiaca, Vascolare e Toracica

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632

Periodicità: Bimestrale

ISSN 0021-9509

Online ISSN 1827-191X

 

The Journal of Cardiovascular Surgery 1998 Ottobre;39(5):551-5

VASCULAR PAPERS 

 ORIGINAL ARTICLES

Thrombolysis with i.v. recombinant human tissue-type plasminogen activator in patients with bypass graft occlusion: a good adjunctive therapeutic mode (preliminary and case reports)

Agresta F., Michelet I., Boni V., Tonietto G.

From the Department of Surgery Ospedale Civile, Vittorio Veneto, Treviso, Italy

Background and methods. The authors report their experience with thrombolytic therapy in seven cases of graft thrombosis managed successfully with low-dose I.V. rt-TPA. In six patients the cause was an anatomical one and so, after the successful lysis, there was enough time to confirm a correct diagnosis and plan the “right” and “less extensive” surgical procedure, obviating it in one case with a “functional” cause of thrombosis.
Results. No complication directly attributable to rt-TPA infusion occurred, and no systemic fibrinogenolysis was registered in any cases. Judging from this experience, I.V. rt-TPA appears safe and effective in patients with graft thrombosis, proving to be a good adjunctive therapeutic mode.
Conclusions. Further studies are needed do delineate more clearly safe indication and the validity of this method.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina